The TICA database data showed that liver cancer patients within the low EM score group had higher sensitivity to CTLA4 inhibitors (p = 0.00015), PD-1 inhibitors (p = 0.0021), and PD-1 inhibitors combined with CTLA4 inhibitors (p = 0.0066) (Figures 7D–F). Here, CTLA4 is linked to liver cancer.